Fig. 2.

Schematic overview of maximum percentage of patients scoring cognitive impaired or those reporting complaints; blood markers showing alterations over time and blood and neuroimaging markers showing associations with cognitive score or complaints, all for chemotherapy-treated patients.

Note. Patients scoring cognitive impaired or reporting complaints were both defined based on (study-specific) norm scores of cross-sectional findings from studies included in this review [14,20,25,31,34,[37], [38], [39]]. Red = blood marker being altered at a given time point over the course of chemotherapy, blue = blood marker and/or neuroimaging metric showing an association with cognitive score at a given time point. White = no changes or association at a given time point. Fading of colors indicates transitioning to other time point, not strength of associations. Short-term = assessment within one week to four months post-chemotherapy. Long-term = assessment within six months to 20 years post-chemotherapy. DWI = diffusion weighted imaging, T₁W = anatomical T₁ weighted imaging, ¹H-MRS = proton magnetic resonance spectroscopy, ¹⁸F-FDG-PET = metabolic fluor-18 fluorodeoxyglucose positron emission tomography.